NeoGenomics

NeoGenomics, Inc. is a clinical laboratory company, which engages in cancer genetics diagnostic testing and pharma services. It operates through the Clinical Services and Pharma Services segments. The Clinical Services segment offers cancer testing services to community-based pathologists, hospitals, academic centers, and oncology groups. The Pharma Services segment focuses on supporting pharmaceutical firms in drug development programs by supporting various clinical trials and research. It also provides testing services in support of its pharmaceutical clients' oncology programs from discovery to commercialization. The company was founded by Michael T. Dent on October 29, 1998 and is headquartered in Fort Myers, FL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

NeoGenomics reports robust Q4 earnings, targets profitability in 2023

NeoGenomics delivered strong financial performance in Q4 2022 and full-year 2022, with a focus on sustainable long-term growth. The company aims to achieve adjusted EBITDA positive by Q4 2023 through strategic initiatives, including revenue growth, margin improvement, and operational efficiencies.

NeoGenomics reports robust Q1 results, eyes growth in diagnostics

NeoGenomics' Q1 performance reflects strong revenue growth and operational improvements, driven by strategic priorities and salesforce optimization.
While facing challenges in market share capture and modalities impact, the company's focus on automation and revenue cycle management presents growth opportunities.
Overall, NeoGenomics is well-positioned to achieve its full-year guidance and capitalize on opportunities in advanced diagnostics and revenue optimization.

NeoGenomics excels in Q2, raises guidance on strong growth prospects

NeoGenomics delivered strong financial results, raised revenue guidance, and improved operational efficiencies. With a focus on NGS portfolio expansion, revenue growth, and strategic planning, the company is well-positioned for future success amidst market challenges.

NeoGenomics reports strong Q3 growth, eyes accelerated breast coverage

NeoGenomics demonstrated robust growth and operational improvements in Q3.
The company's focus on high-value areas like breast cancer is a strategic advantage.
Challenges include potential delays in submissions and ongoing labor inflation concerns.
Opportunities lie in accelerated breast coverage, sales force expansion, and payment efficiency enhancements.

NeoGenomics reports strong Q4 earnings and outlines growth strategies

NeoGenomics delivered strong financial performance in Q4 2023, with revenue growth, improved profitability, and a focus on strategic investments for future growth and operational efficiency.
The company's strengths lie in its strategic focus areas, commitment to value creation, and solid financial position, positioning it well for sustainable success and market leadership.
While facing challenges such as market dynamics and operational hurdles, NeoGenomics has opportunities in expanding market share, product innovation, and strategic partnerships to drive growth and profitability.
Overall, NeoGenomics' performance, strengths, challenges, and opportunities indicate a resilient business poised for continued growth, profitability, and market expansion in the evolving healthcare landscape.

NeoGenomics reports robust Q1 growth, eyes M&A and innovation

NeoGenomics delivered strong financial performance in Q1 2024, driven by revenue growth and operational improvements.
The company's strategic priorities, leadership enhancements, and regulatory outlook bode well for future growth and innovation.
While facing challenges in legal defense and market dynamics, NeoGenomics is well-positioned to leverage opportunities in M&A, product launches, and commercial expansion.

NeoGenomics reports robust Q2 growth amidst legal challenges

NeoGenomics delivered strong financial performance in Q2 2024, with revenue growth, positive adjusted EBITDA, and raised revenue guidance for the year.
The company's strategic focus on innovation, operational efficiency, and growth positions it well to capitalize on the evolving healthcare landscape and increasing demand for advanced diagnostics.
While facing legal challenges, NeoGenomics is actively exploring solutions and remains committed to driving value creation and expanding its market presence through product development and strategic initiatives.

NeoGenomics reports record Q3 earnings, eyes growth through innovation

NeoGenomics delivered strong financial performance in Q3 2024, with record revenues and improved adjusted EBITDA, driven by NGS growth.
The company's strategic focus on sustainable growth, innovation, and financial management strengths position it well for future success.
Challenges lie in addressing profitability evolution, successful Neo Helix integration, and balancing short-term impact with long-term value creation.
Opportunities include Neo Helix development, revenue mix diversification, and achieving the revised adjusted EBITDA guidance range.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Acquisition establishes NeoGenomics as a technology leader in the minimal residual disease (MRD) testing market FT. MYERS, FL / ACCESSWIRE / June 18, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, announced today that it has completed its acquisition of Inivata Ltd, a global, commercial stage liquid biopsy platform company headquartered in Cambridge, England.

NeoGenomics Completes Inivata Acquisition - Combining Best-In-Class Liquid Biopsy Technology with Leading Community Oncology Platform

NeoGenomics (NEO) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front

Moving Average Crossover Alert: NeoGenomics (NEO)

Howard Hughes

HealthEquity

StoneCo

Spotting bloated toxic stocks on a regular basis and abandoning them at the right time is one of the secrets to a winning investment strategy.

Don't Let These 4 Toxic Stocks Erode Your Wealth

FT. MYERS, FL / ACCESSSWIRE / May 10, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced that Douglas VanOort, Executive Chairman, Mark Mallon, Chief Executive Officer, and Kathryn McKenzie, Chief Financial Officer, will be presenting at the Bank of America 2021 Health Care Conference, on Wednesday, May 12, 2021 at 4:15pm ET. The presentation will be webcast live and accessible online via the investors section of the Company's website, www.neogenomics.com.

NeoGenomics To Participate In The Bank of America 2021 Health Care Conference

NeoGenomics (NEO) CEO Mark Mallon on Q1 2021 Results - Earnings Call Transcript

NeoGenomics Inc (NASDAQ: NEO) has agreed to acquire the remaining stake in Inivata Ltd, a commercial-stage liquid biopsy platform company headquartered in England. The acquisition follows a $25 million minority equity investment by NeoGenomics in Inivata in May last year, at which time NeoGenomics was granted a fixed price option to purchase the remainder of Inivata for $390 million.

NeoGenomics Exercises Option To Acquire Remaining Stake In Inivata For $390M

First-Quarter 2021 Results and Highlights: Consolidated revenue increased 9% to $116 million Clinical Services revenue increased 4% to $96 million Pharma Services revenue increased 46% to $19 million Completed the acquisition of Trapelo Health in April FORT MYERS, FL / ACCESSWIRE / May 5, 2021 / NeoGenomics, Inc. (NASDAQ:NEO) (the "Company"), a leading provider of cancer-focused genetics testing services, today announced its first-quarter results for the period ended March 31, 2021. Mark W. Mallon, the Company's CEO said "I couldn't be more excited to be joining NeoGenomics at such a pivotal time in the Company's history.

NeoGenomics Reports 9% Revenue Growth to $116 Million in the First Quarter

Establishes NeoGenomics as a technology leader in the minimal residual disease (MRD) testing market NeoGenomics exercises option struck in May 2020 to purchase remaining equity stake for $390 million Completes $200 million strategic financing with leading oncology-focused specialist investors FT. MYERS, FL / ACCESSWIRE / May 5, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, announced today that it has agreed to acquire Inivata Ltd, a global, commercial stage liquid biopsy platform company headquartered in Cambridge, England.

NeoGenomics to Acquire Inivata - Combining Best-In-Class Liquid Biopsy Technology with Leading Community Oncology Platform

NeoGenomics (NEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

NeoGenomics (NEO) Earnings Expected to Grow: Should You Buy?

SGT Program will provide KRAS G12C testing to eligible patients at no cost, regardless of insurance type. FT. MYERS, FL / ACCESSWIRE / April 19, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, is excited to launch an Amgen-sponsored testing program to support single-gene molecular testing for the biomarker KRAS G12C for eligible lung cancer patients at no cost to the patient.

NeoGenomics Announces the Launch of Biomarker Assist KRAS Single Gene Testing (SGT) Program for Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer Patients

FT. MYERS, FL / ACCESSWIRE / April 13, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced that Douglas VanOort, Chairman and Chief Executive Officer, Doug Brown, Chief Strategy and Corporate Development Officer will be presenting at the 20th Annual Needham Virtual Healthcare Conference 2021, on Thursday, April 15, 2021 at 11:00am ET. The presentation will be webcast live and accessible online via the investors section of the Company's website.

NeoGenomics to Participate in the 20th Annual Needham Virtual Healthcare Conference

AdaptHealth Corp

BellRing Brands Inc

Chart Industries

Lovesac Company

Q2 Hld

Rackspace Technology, Inc.

Small-cap growth stocks can be thick on potential, but thin in news updates and analysis. Here, we look at seven high-potential small caps, and what the pros have to say about them.

7 Super Small-Cap Growth Stocks to Buy

FT MYERS, FL / ACCESSWIRE / April 7, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing and global contract research services, announced today that it plans to release its first quarter 2021, financial results on Wednesday, May 5, 2021. The Company has scheduled a webcast and conference call to discuss their first quarter results on Wednesday, May 5, 2021 at 8:30 AM EDT.

NeoGenomics Schedules its First Quarter 2021 Earnings Release for May 5, 2021

NeoGenomics (NEO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Strength Seen in NeoGenomics (NEO): Can Its 7.9% Jump Turn into More Strength?

Clinical Decision Support to Enable Precision Oncology FT. MYERS, FL / ACCESSWIRE / March 24, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, announced today that it has agreed to acquire Intervention Insights, Inc. d/b/a Trapelo Health, an Information Technology company focused on precision oncology.

NeoGenomics Agrees to Acquire Trapelo Health

Clinical Trial Matching Collaboration Will Enhance Identification of Patients with Any Solid Tumo r Harboring an NRG1 Gene Fusion Identified Using NeoGenomics' Advanced Gene Fusion Panels FORT MYERS, FL and NEW YORK, NY / ACCESSWIRE / March 16, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, and Elevation Oncology, a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers, announced today a collaboration to enhance identification of patients with any solid tumor harboring an NRG1 fusion who may be eligible for enrollment in the Phase 2 CRESTONE study. NeoGenomics is a leading provider of next-generation sequencing (NGS) performing more than 50,000 NGS tests per year.

NeoGenomics and Elevation Oncology Announce Collaboration to Expand Genomic Testing for NRG1 Fusions Across Solid Tumors in Support of the Phase 2 CRESTONE Study

NEW YORK and FORT MYERS, Fla., March 16, 2021 /PRNewswire/ --  Elevation Oncology , a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers, and NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, announced today a collaboration to enhance identification of patients with any solid tumor harboring an NRG1 fusion who may be eligible for enrollment in the Phase 2 CRESTONE study.

Elevation Oncology and NeoGenomics Announce Collaboration to Expand Genomic Testing for NRG1 Fusions Across Solid Tumors in Support of the Phase 2 CRESTONE Study

FT. MYERS, FL / ACCESSWIRE / March 1, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced that Chief Financial Officer Kathryn McKenzie and Doug Brown, Chief Strategy and Corporate Development Officer will be presenting at the Virtual Raymond James 42nd Annual Institutional Investors Conference 2021, on Wednesday, March 3, 2021 at 10:50am ET. The presentation will be webcast live and accessible online via the investors section of the Company's website, www.neogenomics.com.

NeoGenomics To Participate In The Virtual Raymond James 42nd Annual Institutional Investors Conference

NeoGenomics (NEO) CEO Doug VanOort on Q4 2020 Results - Earnings Call Transcript

Shares of NeoGenomics (NASDAQ:NEO) were unchanged after the company reported Q4 results. Quarterly Results Earnings per share rose 40.00% over the past year to $0.14, which beat the estimate of $0.06.

Recap: NeoGenomics Q4 Earnings

Earnings Preview: NeoGenomics (NEO) Q4 Earnings Expected to Decline

ICICI Bank Ltd.

Texas Pacific Land Trust

The S&P 500 Index stocks saw their aggregate trailing 12-month revenue per share increase at a compound average growth rate (CAGR) of 2% per annum over the past five years. The share price of the index has increased 105% over the past five years through Feb. 4.

3 Fast Growing Revenue Stock Picks

Access to industry-leading genomic database and real-world evidence designed to optimize trial design, site selection, clinical trial matching and translational research Access to industry-leading genomic database and real-world evidence designed to optimize trial design, site selection, clinical trial matching and translational research

Parexel and NeoGenomics Announce Strategic Collaboration in Precision Medicine to Improve Study Designs and Accelerate Patient Matching in Oncology Clinical Trials

FORT MYERS, FL / ACCESSWIRE / January 6, 2021 / NeoGenomics, Inc. (NASDAQ:NEO) (the "Company"), a leading provider of cancer-focused genetics testing services and global oncology contract research services, today announced the pricing of concurrent underwritten public offerings of (a) 4,081,632 shares of its common stock at a public offering price of $49.00 per share (the "common stock offering") for gross proceeds to NeoGenomics from the common stock offering of $200.0 million, before deducting the underwriting discounts and commissions and estimated common stock offering expenses payable by NeoGenomics and (b) $300,000,000 aggregate principal amount of its 0.25% convertible senior notes due 2028 (the "notes") (the "notes offering"; collectively with the common stock offering, the "offerings") for gross proceeds to NeoGenomics from the notes offering of $300.0 million, before deducting the underwriting discounts and commissions and estimated notes offering expenses payable by NeoGenomics. In addition, NeoGenomics has granted the underwriters of the offerings a 30-day option to purchase up to an additional (a) 612,244 shares of its common stock at the public offering price, less underwriting discounts and commissions, and (b) $45,000,000 aggregate principal amount of the notes, less underwriting discounts and commissions and solely to cover over-allotments with respect to the notes offering.

NeoGenomics Announces Pricing of Public Offerings of Common Stock and Convertible Senior Notes

FORT MYERS, FL / ACCESSWIRE / January 5, 2021 / NeoGenomics, Inc. (NASDAQ:NEO) (the "Company"), a leading provider of cancer-focused genetics testing services and global oncology contract research services, today announced that it has commenced proposed underwritten public offerings of approximately $200,000,000 of newly issued shares of common stock (the "common stock offering") and $250,000,000 aggregate principal amount of convertible senior notes due 2028 (the "notes") (the "notes offering"). In addition, NeoGenomics expects to grant the underwriters of the offerings a 30-day option to purchase up to an additional (a) $30,000,000 of shares of its common stock at the public offering price, less underwriting discounts and commissions, and (b) $37,500,000 aggregate principal amount of the notes, less underwriting discounts and commissions and solely to cover over-allotments with respect to the notes offering.

News for NeoGenomics Stock (NEO)